Atrial natriuretic peptide stability.
OBJECTIVE
Atrial natriuretic peptide (ANP) is a key regulator in the homeostasis of water excretion and has emerged as an important prognostic marker for symptomatic chronic heart failure (CHF). The stability of ANP represents a crucial factor in assessing its use as a cardiac biomarker. Accordingly, we assessed the stability of ANP in blood samples collected from healthy controls and CHF subjects for a 12 month period.


METHODS
Blood samples from 10 healthy controls and 12 symptomatic CHF subjects with left ventricular systolic dysfunction were drawn. Determination of plasma ANP was performed by a standardized radioimmunoassay protocol.


RESULTS
The ANP levels of healthy subjects were 68.5+/-11.6 pg/mL at baseline and 69.9+/-17.2 pg/mL at 12 months (p=0.71). The ANP concentrations of CHF subjects were 199.25+/-44.8 pg/mL at baseline and 197.83+/-47.4 pg/mL at 12 months (p=0.70) respectively.


CONCLUSIONS
ANP is a stable molecule with no evidence of degradation when stored at -80 degrees C.
Albert Einstein College of Medicine, Division of Cardiology, Bronx, NY 10461, USA. RZOLTY@montefiore.org
Ronald
R
Zolty
Carol
C
Bauer
Pamila
P
Allen
Maureen
M
Garrity
Timothy J
TJ
Vittorio
D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood*; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D055550:Protein Stability; D013816:Thermodynamics
D009320:Atrial Natriuretic Factor